Immunogenicity and safety of a multi-human dose formulation of Biological E’s 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14®) administered to 6–8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled study

Immunogenicity and safety of a multi-human dose formulation of Biological E’s 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14®) administered to 6–8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled study

BackgroundPneumococcal conjugate vaccines (PCVs) have considerably reduced the burden of invasive pneumococcal disease (PD) worldwide. Consequently, though, there has been an increase in non-vaccine serotype-induced PD particularly at both the extremes of age. Biological E has developed a 14-valent...

Full description

Saved in:
Bibliographic Details
Main Authors: Subhash Thuluva, Ramesh V. Matur, Subbareddy Gunneri, Rammohan Reddy Mogulla, Kamal Thammireddy, Kalyan Kumar Peta, Piyush Paliwal, Niranjana S. Mahantshetti, Ramesh Kumar Banala, Prashanth Siddaiah
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Immunology
Subjects:
vaccine
pneumococcal conjugate vaccine
PCV
serotype 6A
infant immunization
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1550227/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1550227/full

Similar Items